痕量胺相关受体1激动剂作为发作性睡病治疗药物
该研究在小鼠发作性睡病模型中评估TAAR1激动剂对睡眠/觉醒及猝倒的影响。RO5256390显著减少野生型小鼠REM睡眠,该效应在Taar1敲除小鼠中消失;两种TAAR1激动剂均促进觉醒、减少猝倒发作次数与时间。结果提示TAAR1激动可能是发作性睡病的新治疗通路。
要点
- TAAR1激动剂RO5256390减少野生型小鼠REM睡眠,效应依赖TAAR1。
- 部分激动剂RO5263397促进觉醒并抑制非REM睡眠。
- 两种TAAR1激动剂在发作性睡病模型中减轻猝倒。
核心结论
- TAAR1激动可能是治疗发作性睡病这一孤儿病的新治疗通路。
- 共同潜在机制可能是抑制快速眼动睡眠。
研究设计与样本
- 第一项实验在雄性纯合B6-Taar1tm1(NLSLacZ)Blt(Taar1敲除)与野生型小鼠中手术植入记录脑电图、肌电图、运动活动和体温,评估TAAR1激动剂RO5256390对睡眠/觉醒及生理参数的效果。
- 第二项实验在两种小鼠发作性睡病模型中评估TAAR1完全激动剂RO5256390与部分激动剂RO5263397对睡眠/觉醒、运动活动、体温及猝倒的影响。
主要发现
- RO5256390显著减少野生型小鼠快速眼动睡眠,该效应在Taar1敲除小鼠中消失。
- TAAR1部分激动剂RO5263397促进觉醒并抑制非快速眼动睡眠。
- 两种化合物在最高测试剂量下均降低两种发作性睡病模型中的体温。
- 两种TAAR1化合物在发作性睡病模型中均减轻猝倒,疗效通过减少猝倒发作次数与猝倒时间实现。
临床怎么用
- TAAR1激动剂可能作为发作性睡病的新治疗方向,尤其针对猝倒症状。
- 其治疗获益可能与抑制快速眼动睡眠相关。
局限性
- 证据仅来自小鼠模型,尚未在人类中验证。
- 研究未报告临床试验数据或长期安全性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Narcolepsy, a disorder of rapid eye movement (REM) sleep, is characterized by excessive daytime sleepiness and cataplexy, a loss of muscle tone triggered by emotional stimulation. Current narcolepsy pharmacotherapeutics include controlled substances with abuse potential or drugs with undesirable side effects. As partial agonists at trace amine-associated receptor 1 (TAAR1) promote wakefulness in mice and rats, we evaluated whether TAAR1 agonism had beneficial effects in two mouse models of narcolepsy. METHODS: In the first experiment, male homozygous B6-Taar1tm1(NLSLacZ)Blt (Taar1 knockout) and wild-type mice were surgically implanted to record electroencephalogram, electromyogram, locomotor activity, and body temperature, and the efficacy of the TAAR1 agonist, RO5256390, on sleep/wake and physiological parameters was determined. In the second experiment, the effects of the TAAR1 full agonist RO5256390 and partial agonist RO5263397 on sleep/wake, locomotor activity, body temperature, and cataplexy were assessed in two mouse narcolepsy models. RESULTS: RO5256390 profoundly reduced rapid eye movement sleep in wild-type mice; these effects were eliminated in Taar1 knockout mice. The TAAR1 partial agonist RO5263397 also promoted wakefulness and suppressed nonrapid eye movement sleep. Both compounds reduced body temperature in the two narcolepsy models at the highest doses tested. Both TAAR1 compounds also mitigated cataplexy, the pathognomonic symptom of this disorder, in the narcolepsy models. The therapeutic benefit was mediated through a reduction in number of cataplexy episodes and time spent in cataplexy. CONCLUSIONS: These results suggest TAAR1 agonism as a new therapeutic pathway for treatment of this orphan disease. The common underlying mechanism may be the suppression of rapid eye movement sleep.
引用
- Black SW, Schwartz MD, Chen TM, et al. Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics. Biol Psychiatry. 2016. PMID: 27919403. doi:10.1016/j.biopsych.2016.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。